New phase 3 trial to assess impact on disease progression, function and quality of life

Original title: “Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease”

The strain of the virus that's responsible for the current outbreak has no specific treatments or preventive measures. Three new clinical trials could provide possible breakthroughs. There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope The strain of the virus that's responsible for the current outbreak has no specific treatments or preventive measures. Three new clinical trials could provide possible breakthroughs. "We urgently need treatments that can help people affected by Bundibugyo virus disease," says Amanda Rojek, a physician scientist at the University of Oxford — that's a rarer species of Ebola than the much-researched Zaire strain behind many previous outbreaks. But because of that rarity, there are no specialized treatments to give patients. Nor are there drugs that might protect those exposed to the virus from getting sick. ... That reality is changing. Clinical trials are underway, or soon will be, to test new tools that health officials hope could help turn the tide against an outbreak that has already killed over 500 people and sickened more than 1,560 — and which some say could become the largest Ebola outbreak ever. BARDA is a U.S. government agency within the Department of Health and Human Services and the government has donated the doses necessary for the clinical trial, according to Vasee Moorthy, WHO's research and development lead for the outbreak. Each drug will be tested alone, and in combination, against the current standard of care — supportive therapy that aims to replace lost fluids and manage pain. A health worker takes a woman's temperature as part of Ebola screening efforts in Goma, Democratic Republic of Congo. As part of the effort to quash the outbreak, the first patients have been enrolled in a clinical trial to test two drugs against the Bundibugyo strain of the virus that is spreading there.

Original title: “There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope : NPR”

EMA’s human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. A phased…

Original title: “EMA fast tracks review of a medicine for metastatic pancreatic cancer”

Six new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended six medicines for approval at its June 2026 meeting.The committee recommended…, CHMP statistics Key figures from the June 2026 CHMP meeting are represented in the graphic below. © European Medicines Agency , CHMP statistics:…, Positive rec

Original title: “Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026”

CVMP opinions on veterinary medicinal productsThe Committee adopted a negative opinion for a marketing authorisation for Scovella (velagliflozin), a product classified as…

Original title: “Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-18 June 2026”

The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose.

Original title: “FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose”

Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.

Original title: “Elicio crashes on midstage pancreatic cancer miss but will advance to Phase 3”